Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.53 |
| ▸ | SCN1A | P35498 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22836449 | 0.90 | HTR2A (0.47) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL22849201 | 0.90 | HTR2A (0.47) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL26352717 | 0.90 | HTR2A (0.47) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL31409498 | 0.84 | HTR2A (0.53) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL13154008 | 0.84 | HTR2C (0.59) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL31312250 | 0.79 | HTR2A (0.53) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL31533425 | 0.79 | HTR2A (0.55) | MAOASCN1ASCN5ASCN9AHTR2A | |
| SCHEMBL24607464 | 0.79 | SCN1A (0.40) | MAOASCN1ASCN5ASCN9A | |
| SCHEMBL29502309 | 0.79 | SCN1A (0.40) | MAOASCN1ASCN5ASCN9A | |
| Trifluoroacetic Acid SCHEMBL3089861 | 0.78 | HTR2A (0.50) | MAOASCN1ASCN5ASCN9AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAOA 2771/4885SCN1A 4737/4885SCN5A 4752/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | MAOA 3748/4885SCN1A 4804/4885SCN5A 4785/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAOA 2771/4885SCN1A 4737/4885SCN5A 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.